NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Minoryx Therapeutics

Minoryx Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttp://www.minoryx.com/

Last Round

Grant

May 28, 2024

Total Funding Raised

$137.6M

Company Overview

Minoryx Therapeutics is a clinical-stage biotechnology company that discovers and develops novel treatments for severe, orphan diseases of the central nervous system (CNS) with high unmet medical need.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

orphan drugsrare disease therapeuticsX-linked AdrenoleukodystrophyX-ALDleriglitazoneCNS disease treatmentneurodegenerative diseasePPAR gamma agonistclinical stage biotechdrug licensingbrain penetrantneuroinflammationmitochondrial dysfunctionOrphan Drug DesignationFriedreich's AtaxiaFRDARett syndrome

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Minoryx Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Minoryx Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Minoryx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 28, 2024
Series CMay 31, 2022
DebtOct 30, 2020
Series BSep 26, 2018
Series AOct 14, 2015
Seed
Oct 1, 2015

Key People

Founding team and executive leadership

Marc Martinell

Co-founder & CEO

Founding Team

Minoryx Therapeutics Investors

Notable investors and investment history

Minoryx Therapeutics investors
InvestorRounds
Federal Holding and Investment CompanySeries B, Series C
Roche Venture FundSeries B, Series A, Series C
CDTI InnvierteSeries C
Fund+Series C, Series B
Ysios CapitalSeries B, Series C, Series A
Wallonie EntreprendreSeries B, Series C
Horizon 2020 ProgrammeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 25, 2026

    Monthly visitors grew 107% MoM, reaching 9.6K.

  • May 1, 2025

    Monthly visitors increased 42% MoM, reaching 3.7K.

Minoryx Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Minoryx Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Minoryx Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range33
Year Founded2011
Last FundingMay 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.